Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cybin ( (HELP) ) has shared an update.
On February 13, 2026, Cybin Inc., operating as Helus Pharma, filed a Form 6-K with the U.S. Securities and Exchange Commission for February 2026, reinforcing its status as a foreign private issuer and integrating several key disclosures into its existing Canadian shelf prospectus registration. The filing delivered unaudited condensed interim consolidated financial statements and related certifications for the three and nine months ended December 31, 2025, revealing a sharp increase in total assets to $290.1 million driven mainly by a cash balance of $195.1 million, alongside a wider accumulated deficit of $342.5 million that underscores the company’s continued heavy investment in research and administration.
The report showed shareholders’ equity climbing to $273.9 million from $165.0 million as of March 31, 2025, supported by higher share capital, new pre-funded warrants, expanded warrant reserves, and the introduction of a restricted share unit reserve. For the quarter and nine-month period ended December 31, 2025, research, general and administrative, and share-based compensation expenses all increased versus the restated prior-year periods, highlighting a more aggressive spending profile that may support future growth but also heightens near-term losses and risk for equity holders.
The most recent analyst rating on (HELP) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Cybin stock, see the HELP Stock Forecast page.
More about Cybin
Cybin Inc., doing business as Helus Pharma, is a Toronto-based biopharmaceutical company focused on developing psychedelic-derived therapeutics. The firm operates under International Financial Reporting Standards and is listed as a foreign private issuer in the United States, targeting investors through cross-border securities registrations.
Average Trading Volume: 661,858
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
For an in-depth examination of HELP stock, go to TipRanks’ Overview page.